Navigation Links
Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients
Date:6/15/2009

CHICAGO, June 15 /PRNewswire-USNewswire/ -- Vitamin D deficiency was found to be prevalent in cancer patients regardless of nutritional status, according to the results of a recent study conducted at Cancer Treatment Centers of America (CTCA). Based on these results, CTCA researchers determined that screening for vitamin D deficiency and aggressive vitamin D repletion should be considered for all people with cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090612/CTCALOGO)

"While emerging evidence suggests the protective role of vitamin D in cancer, vitamin D status is not routinely assessed in cancer patients despite the high prevalence of malnutrition in this population," said Carolyn Lammersfeld, national director of nutrition for CTCA and a principal investigator in the study.

During the study, a consecutive case series of 737 cancer patients (302 male and 435 female) seen at CTCA between January - June 2008, were assessed for nutritional status and categorizes into three distinct classes of nutritional status: well nourished, moderately malnourished and severely malnourished. The mean age at presentation was 55.7 years (SD = 10.2) and the most common cancer types were lung (133, 18%), breast (131, 17.8%), colorectal (97, 13.2%), pancreatic (86, 11.7%), prostate (44, 6%) and ovarian (38, 5.2%).

Before the study, the researchers hypothesized that malnutrition could contribute to vitamin D deficiency and therefore expec
'/>"/>

SOURCE Cancer Treatment Centers of America
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2010)... DALLAS, Texas, September 2, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; ... first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
(Date:9/2/2010)... Schein, Inc. (Nasdaq: HSIC ), the ... to office-based practitioners, is helping a record number ... and carrying backpacks filled with school supplies and ... Back-to-School program.  This year, the Back-to-School program is ... and Canadian cities.  Since its creation in 1998, ...
(Date:9/1/2010)... CITY, Fla., Sept. 1 Gulf Coast ... of Radiology-accredited radiation oncology center, introduces the Elekta ... at the center,s Open House on Thursday, September ...  Gulf Coast Cancer Treatment Center (GCCTC) is located ... oncologists Dr. D.B. Hurst and Dr. Jefferson Trupp ...
Breaking Medicine Technology:Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 2Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 3Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 4Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 5Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 6Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 7Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 813th Annual Henry Schein Back-to-School Program Serves Record Number of Children 213th Annual Henry Schein Back-to-School Program Serves Record Number of Children 3Open House at Gulf Coast Cancer Treatment Center Introduces Elekta Synergy® to Community 2ApexTwo and SugarCRM Announce New Implementation Partnership 71891 1ApexTwo and SugarCRM Announce New Implementation Partnership 71891 2 2418 5 Million New Jersey Medical Malpractice Birth Injury Verdict Due To Cerebral Palsy Caused By A Delayed C Section 71887 1 2418 5 Million New Jersey Medical Malpractice Birth Injury Verdict Due To Cerebral Palsy Caused By A Delayed C Section 71887 2Cost Savings from Mobile Health Monitoring to Reach 241 9 billion to 245 8 Billion Globally by 2014 says Juniper Research 71883 1Cost Savings from Mobile Health Monitoring to Reach 241 9 billion to 245 8 Billion Globally by 2014 says Juniper Research 71883 2Cost Savings from Mobile Health Monitoring to Reach 241 9 billion to 245 8 Billion Globally by 2014 says Juniper Research 71883 3
... is Prostate Cancer Awareness Month, MIAMI and PALM ... Month, and the CyberKnife Centers of Miami and,Palm Beach ... surgery and long treatment courses of radiation. Prostate cancer ... the US., Morse CyberKnife CEO, James G. Schwade, ...
... N.Y., Sept. 2 The many recent reports,documenting ... in,animal models of human disease may actually be ... siRNA to activate an immune,response, according to a ... 9) of ,Human Gene Therapy, a peer-reviewed journal ...
Other Medicine Technology:Previous Claims of siRNA Therapeutic Effects Called into Question by Report in 'Human Gene Therapy' 2Previous Claims of siRNA Therapeutic Effects Called into Question by Report in 'Human Gene Therapy' 3
(Date:9/2/2010)... Dotinga HealthDay Reporter , , THURSDAY, Sept. 2 ... news stories about the young, possibly because it makes ... , , "The more time they spent with negative news ... may get some self-esteem boost out of this," said ... State University,s School of Communication. As for young ...
(Date:9/2/2010)... of as trunks in the tree of life. All multi-cellular ... variety other cellskidney, brain, heart or skin, for example. One ... virtually any cell type in the body, making them a ... of age-old diseases or even regrowing defective body parts. , ... shown for the first time that a gene called Myc ...
(Date:9/2/2010)... emergency medical services (EMS) agencies from across the country ... a tool that might point to potential patient safety ... School of Medicine. , The study , ... Prehospital Emergency Care and now available online, analyzed ... and Canada. Researchers adapted a survey used in other ...
(Date:9/2/2010)... treatments build on the benefits of drug therapy, ... and Dr. Kenneth Holroyd from Ohio University in ... various treatment combinations for severe migraine drug ... that those patients receiving the behavioral management program ... their ability to use behavioral skills to effectively ...
(Date:9/1/2010)... New research from the University of New Hampshire ... teenagers who use marijuana are more likely to move ... is overblown. , Whether teenagers who smoked pot ... more to do with life factors such as employment ... fact, the strongest predictor of whether someone will use ...
Breaking Medicine News(10 mins):Health News:Seniors Get Boost From Bad News About the Young 2Health News:Study finds that cancer-causing gene crucial in stem cell development 2Health News:Study finds that cancer-causing gene crucial in stem cell development 3Health News:Safety cultures in EMS agencies vary widely, Pitt study finds 2Health News:Head start for migraine sufferers 2Health News:Risk of marijuana's 'gateway effect' overblown, new UNH research shows 2
... a rate not seen in more than twenty years, creating a ... for small business is being called a top priority at a ... (NFIB) and America,s Health Insurance Plans (AHIP). , ... ...
... benefits can last for years, researchers say , , MONDAY, March ... play: A new study finds the pastime can help adults ... the first parts of vision to be affected by aging. ... minor changes in shades of grey against a uniform background ...
... 44% Over Prior YearVANCOUVER, March 30 /PRNewswire-FirstCall/ - Response ... recorded total revenues of $5,876,337 and a net loss ... ended December 31, 2008. Additionally, the Company announced that ... million in working capital. For a further discussion of ...
... offer improved aesthetic results will help drive the dental ... Mass., March 30 According to Millennium Research Group,s ... Implants 2009 report, although the current economic crisis ... term, the US dental implant market will recover after ...
... ANN ARBOR, Mich., March 30 A ... effective, cheaper medications may create barriers that lead people ... Thomson Reuters study. As a result, patients ultimately require ... called "step therapy," requires health plan members to try ...
... Well Tolerated Throughout Two-Year Study- Conference Call Scheduled ... March 30, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... results from BLOOM (Behavioral modification and Lorcaserin for ... pivotal trials evaluating the safety and efficacy of ...
Other Medicine News:Health News:BestHealthcareRates.com Reports Highest Cancellation Rate of Employee Benefit Plans in More Than Two Decades 2Health News:BestHealthcareRates.com Reports Highest Cancellation Rate of Employee Benefit Plans in More Than Two Decades 3Health News:BestHealthcareRates.com Reports Highest Cancellation Rate of Employee Benefit Plans in More Than Two Decades 4Health News:Response Biomedical Corporation Reports 2008 Financial Results 2Health News:Response Biomedical Corporation Reports 2008 Financial Results 3Health News:Response Biomedical Corporation Reports 2008 Financial Results 4Health News:Response Biomedical Corporation Reports 2008 Financial Results 5Health News:Dental Implant Market to Exceed $1 Billion by 2013 Despite Current Economic Slowdown 2Health News:Thomson Reuters Study Finds Step Therapy Programs May Increase Overall Healthcare Costs for Employers 2Health News:Thomson Reuters Study Finds Step Therapy Programs May Increase Overall Healthcare Costs for Employers 3Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 2Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 3Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 4Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 5Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 6Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 7Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 8Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 9Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 10Health News:Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints 11
Finstruments 96 well washer and Cellwasher. Multi-function with touch programmable display....
The Finstrip combines high performance and flexibility with reliability, simplicity and ease of use....
... has set a standard for ultra-fast washing ... instrument not only processes all 384 wells ... further boost wash performance. This wash procedure ... times as no transport steps to index ...
... Bio-Rad's Model 1575 immunowash ... control of needle position ... routines and maximize wash ... a large choice of ...
Medicine Products: